Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Florbetaben→

Florbetaben Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
902143-01-5
Molecular formula
C21H26[18F]NO3
Molecular weight
358.4 g/mol
Drug class
18F-labelled amyloid beta PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds fibrillar amyloid beta plaques in the brain. Positron emission tomography detects the radiotracer distribution to estimate the presence or absence of amyloid pathology; it is not a treatment for Alzheimer disease.
Indications / reported uses
  • PET imaging of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer disease or other causes of cognitive decline; scan results must be interpreted with clinical assessment

Sources: US DailyMed — NEURACEQ (florbetaben F18) · EMA EPAR — Neuraceq · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Florbetaben Environmental Risk Assessment (ERA) (the Florbetaben ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.